Not to mention Opthea had a pretty complicated funding arrangement with "DFA Investors" Carlyle and Abingworth whereby they provided funds and took a big chunk of future benefits. And the deal came with fishhooks which could now kill the company (penalty payments of up to $1 billion!)
Neuren has no such baggage or fishhooks with NNZ-2591.
But it just shows hard it is to fund through Phase 3 without making some big compromises. Neuren arguably did their big compromise for trofinitide with Acadia.
But for NNZ-2591 no compromises are required, and we're talking about multiple Phase 3s!
Another reason why Neuren should be 10x where Opthea was last week.
NEU Price at posting:
$12.47 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)